启迪药业(000590) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 84,579,135.01, representing a 4.14% increase year-over-year, while the year-to-date revenue reached CNY 274,629,835.65, up 16.10% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was CNY 47,608.94, a significant decrease of 98.85% year-over-year, with a year-to-date net profit of CNY 6,430,149.78, down 59.04% compared to the previous year[5]. - The basic and diluted earnings per share for Q3 2023 were both CNY 0.0002, reflecting a decline of 98.84% year-over-year, while the year-to-date earnings per share were CNY 0.0269, down 58.99%[5]. - Total operating revenue for Q3 2023 reached CNY 274.63 million, an increase of 16.06% compared to CNY 236.55 million in Q3 2022[17]. - Net profit for Q3 2023 was CNY 6.58 million, a decrease of 58.37% from CNY 15.82 million in Q3 2022[18]. - Basic and diluted earnings per share for Q3 2023 were CNY 0.0269, down from CNY 0.0656 in Q3 2022[18]. Assets and Liabilities - The total assets at the end of Q3 2023 were CNY 1,117,443,922.78, a decrease of 4.23% from the end of the previous year[5]. - The company's current assets decreased to CNY 483,389,605.26 from CNY 529,109,884.24, representing a reduction of about 8.7%[14]. - Total liabilities as of the end of Q3 2023 amounted to CNY 408.56 million, a decrease from CNY 464.26 million at the end of Q3 2022[17]. - The total equity attributable to shareholders of the parent company was CNY 704.90 million, an increase from CNY 698.47 million year-over-year[17]. Cash Flow - The cash flow from operating activities for the year-to-date period was negative CNY 21,039,216.74, representing a decline of 318.23% compared to the same period last year[8]. - The net cash flow from operating activities for Q3 2023 was -21,039,216.74, a decrease from 9,640,827.45 in Q3 2022[21]. - Total cash inflow from investment activities was 272,809,852.65, down from 758,163,813.18 in the same period last year[21]. - The net cash flow from investment activities was -44,024,157.45, compared to -83,070,258.49 in Q3 2022[21]. - Cash inflow from financing activities totaled 20,023,378.16, an increase from 2,000,000.00 in Q3 2022[21]. - The net cash flow from financing activities was -20,141,303.34, compared to -155,433.03 in the previous year[21]. - The total cash and cash equivalents at the end of Q3 2023 were 149,608,547.16, down from 172,776,416.55 at the end of Q3 2022[21]. Expenses - The company reported a 51.72% increase in selling expenses, totaling CNY 64,758,425.58, primarily due to the impact of the merger with Guangdong Xiantong and increased product promotion costs[8]. - The financial expenses increased by 150.13% to CNY 1,538,090.95, attributed to higher interest expenses and reduced interest income[8]. - The company reported a decrease in financial expenses, with interest expenses at CNY 3.50 million compared to CNY 0.56 million in the previous year[17]. - The company's R&D expenses increased to CNY 9.25 million, representing a rise of 19.56% compared to CNY 7.74 million in the previous year[17]. Investments - The company experienced a 119.05% increase in trading financial assets, reaching CNY 55,000,000.00, mainly due to the purchase of structured deposits[8]. - The company reported a significant decrease in investment income, down 73.68% to CNY 612,079.76, due to reduced returns from structured deposit investments[8]. - The company reported an increase in financial assets at fair value, rising to CNY 55,000,000.00 from CNY 25,108,638.89, which is an increase of approximately 118.5%[14]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,233, with the largest shareholder, Tsinghua Tongfang Co., Ltd., holding 29.41% of the shares[10]. Strategic Outlook - The company has not reported any significant new strategies or product developments in the current quarter[12]. - The company plans to continue focusing on market expansion and new product development in the upcoming quarters[16]. Accounting Changes - The company implemented new accounting standards starting in 2023, affecting the financial statements[22]. - The company did not undergo an audit for the Q3 2023 report[22].